GSK
Price
$40.83
Change
-$0.65 (-1.57%)
Updated
Sep 12 closing price
Capitalization
82.17B
44 days until earnings call
NVS
Price
$124.12
Change
-$3.58 (-2.80%)
Updated
Sep 12 closing price
Capitalization
240.38B
43 days until earnings call
Interact to see
Advertisement

GSK vs NVS

Header iconGSK vs NVS Comparison
Open Charts GSK vs NVSBanner chart's image
GSK
Price$40.83
Change-$0.65 (-1.57%)
Volume$4.74M
Capitalization82.17B
Novartis AG
Price$124.12
Change-$3.58 (-2.80%)
Volume$1.86M
Capitalization240.38B
GSK vs NVS Comparison Chart in %
Loading...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GSK vs. NVS commentary
Sep 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Buy and NVS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 15, 2025
Stock price -- (GSK: $40.83 vs. NVS: $124.12)
Brand notoriety: GSK and NVS are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GSK: 101% vs. NVS: 119%
Market capitalization -- GSK: $82.17B vs. NVS: $240.38B
GSK [@Pharmaceuticals: Major] is valued at $82.17B. NVS’s [@Pharmaceuticals: Major] market capitalization is $240.38B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $677.17B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $89.7B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GSK’s FA Score shows that 2 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).

  • GSK’s FA Score: 2 green, 3 red.
  • NVS’s FA Score: 3 green, 2 red.
According to our system of comparison, GSK is a better buy in the long-term than NVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GSK’s TA Score shows that 6 TA indicator(s) are bullish while NVS’s TA Score has 6 bullish TA indicator(s).

  • GSK’s TA Score: 6 bullish, 3 bearish.
  • NVS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, GSK is a better buy in the short-term than NVS.

Price Growth

GSK (@Pharmaceuticals: Major) experienced а +0.81% price change this week, while NVS (@Pharmaceuticals: Major) price change was -4.32% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.12%. For the same industry, the average monthly price growth was +1.69%, and the average quarterly price growth was +12.75%.

Reported Earning Dates

GSK is expected to report earnings on Oct 29, 2025.

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-0.12% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVS($240B) has a higher market cap than GSK($82.2B). GSK (18.24) and NVS (18.09) have similar P/E ratio . NVS YTD gains are higher at: 32.143 vs. GSK (24.823). NVS has higher annual earnings (EBITDA): 22.7B vs. GSK (8.61B). NVS has more cash in the bank: 7B vs. GSK (3.62B). GSK has less debt than NVS: GSK (17.4B) vs NVS (32.6B). NVS has higher revenues than GSK: NVS (55.2B) vs GSK (31.6B).
GSKNVSGSK / NVS
Capitalization82.2B240B34%
EBITDA8.61B22.7B38%
Gain YTD24.82332.14377%
P/E Ratio18.2418.09101%
Revenue31.6B55.2B57%
Total Cash3.62B7B52%
Total Debt17.4B32.6B53%
FUNDAMENTALS RATINGS
GSK vs NVS: Fundamental Ratings
GSK
NVS
OUTLOOK RATING
1..100
4035
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
14
Undervalued
PROFIT vs RISK RATING
1..100
6515
SMR RATING
1..100
4029
PRICE GROWTH RATING
1..100
5452
P/E GROWTH RATING
1..100
2680
SEASONALITY SCORE
1..100
n/a65

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GSK's Valuation (6) in the Pharmaceuticals Major industry is in the same range as NVS (14). This means that GSK’s stock grew similarly to NVS’s over the last 12 months.

NVS's Profit vs Risk Rating (15) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (65). This means that NVS’s stock grew somewhat faster than GSK’s over the last 12 months.

NVS's SMR Rating (29) in the Pharmaceuticals Major industry is in the same range as GSK (40). This means that NVS’s stock grew similarly to GSK’s over the last 12 months.

NVS's Price Growth Rating (52) in the Pharmaceuticals Major industry is in the same range as GSK (54). This means that NVS’s stock grew similarly to GSK’s over the last 12 months.

GSK's P/E Growth Rating (26) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVS (80). This means that GSK’s stock grew somewhat faster than NVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GSKNVS
RSI
ODDS (%)
Bearish Trend 4 days ago
54%
Bearish Trend 4 days ago
47%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
37%
Bullish Trend 4 days ago
40%
Momentum
ODDS (%)
Bullish Trend 4 days ago
65%
Bearish Trend 4 days ago
52%
MACD
ODDS (%)
Bullish Trend 4 days ago
58%
Bearish Trend 4 days ago
48%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
60%
Bearish Trend 4 days ago
43%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
53%
Bullish Trend 4 days ago
46%
Advances
ODDS (%)
Bullish Trend 11 days ago
59%
Bullish Trend 11 days ago
49%
Declines
ODDS (%)
N/A
Bearish Trend 6 days ago
45%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
45%
Bullish Trend 4 days ago
55%
Aroon
ODDS (%)
Bullish Trend 4 days ago
48%
Bullish Trend 4 days ago
41%
View a ticker or compare two or three
Interact to see
Advertisement
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IYT70.74-0.28
-0.39%
iShares Transportation Average ETF
AVLV72.00-0.46
-0.64%
Avantis US Large Cap Value ETF
DEEP36.61-0.26
-0.71%
Acquirers Small and Micro Deep Value ETF
XTL137.77-2.56
-1.82%
SPDR® S&P Telecom ETF
AZNH47.43-0.88
-1.82%
ASTRAZENECA PLC ADRHEDGED AZNH

GSK and

Correlation & Price change

A.I.dvisor indicates that over the last year, GSK has been closely correlated with NVS. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GSK jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GSK
1D Price
Change %
GSK100%
-1.57%
NVS - GSK
68%
Closely correlated
-2.80%
AZN - GSK
62%
Loosely correlated
-1.90%
PFE - GSK
58%
Loosely correlated
-3.98%
SNY - GSK
51%
Loosely correlated
-1.30%
JNJ - GSK
50%
Loosely correlated
-0.25%
More

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
-2.80%
GSK - NVS
67%
Closely correlated
-1.57%
AZN - NVS
60%
Loosely correlated
-1.90%
PFE - NVS
58%
Loosely correlated
-3.98%
JNJ - NVS
54%
Loosely correlated
-0.25%
SNY - NVS
50%
Loosely correlated
-1.30%
More